65,437 trials
Growth Hormone Deficiency in Children
Primary: Height Velocity: In-trial Observation Period — 11.8; 11.2 centimeters per year (cm/year)
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage IV Bladder Urothelial Carcinoma AJCC v7
Primary: Progression-free Survival (PFS) — 11.4 months
Pain
Primary: Pain Ratings — 3.60; 4.69; 4.83; 5.41 units on a scale — p=.05
Diabetes Mellitus · Covid19
Primary: Mean Absolute Relative Difference (MARD) — 10.1 percentage of MARD
Type 1 Diabetes · Pregnancy
Primary: Time in Target Glucose Range — 78.6 percent time
Rhytides · Wrinkle
Primary: Subject Satisfaction — 2.8 score on a scale
Virus Diseases · RNA Virus Infections · Respiratory Tract Infections
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain — 603.7; 595.6; 630.6; 96.3 titers
B-cell Lymphomas (Phase 1) · Advanced Solid Tumors (Phase 1) · Diffuse Large B-cell Lymphoma (Phase 2)
Primary: Recommended Phase 2 Dose (RP2D) of Tazemetostat as a Single-Agent and in Combination With Prednisolone (Phase 1 Only) — 800 mg BID
Tobacco Use Disorder · HIV
Primary: Number of Participants Achieving 7-day Point Prevalence Abstinence From Tobacco Use — 38; 22; 217; 229 Participants
Acne Scars
Primary: Acne Scar Improvement — 0.26 units on a scale
HIV Infections
Primary: Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms — 2; 0 Participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single…
Type 1 Diabetes · Hypoglycemia · High Blood Sugar
Primary: Change in Personal CGM Use — 22; 4 Participants
Prematurity
Primary: Full Scale IQ, Performance IQ, Verbal IQ, Executive Function — 79; 91; 103; 83 standardized score on a scale
Postoperative Urinary Retention · Total Hip Arthroplasty · Total Knee Arthroplasty
Primary: Number of Patients Who Developed Postoperative Urinary Retention (POUR), Unable to Void a Volume Greater Than or Equal to 30ml/hr — 4; 5 Participants